MA46973A - Polymorphes de sépiaptérine et leurs sels - Google Patents

Polymorphes de sépiaptérine et leurs sels

Info

Publication number
MA46973A
MA46973A MA046973A MA46973A MA46973A MA 46973 A MA46973 A MA 46973A MA 046973 A MA046973 A MA 046973A MA 46973 A MA46973 A MA 46973A MA 46973 A MA46973 A MA 46973A
Authority
MA
Morocco
Prior art keywords
sepiapterin
polymorphs
salts
sepiapterin polymorphs
Prior art date
Application number
MA046973A
Other languages
English (en)
Inventor
Daniel E Levy
Original Assignee
Censa Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Censa Pharmaceuticals Inc filed Critical Censa Pharmaceuticals Inc
Publication of MA46973A publication Critical patent/MA46973A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA046973A 2016-11-29 2017-11-28 Polymorphes de sépiaptérine et leurs sels MA46973A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662427686P 2016-11-29 2016-11-29
US201762546390P 2017-08-16 2017-08-16

Publications (1)

Publication Number Publication Date
MA46973A true MA46973A (fr) 2019-10-09

Family

ID=62241930

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046973A MA46973A (fr) 2016-11-29 2017-11-28 Polymorphes de sépiaptérine et leurs sels

Country Status (13)

Country Link
US (4) US11072614B2 (fr)
EP (1) EP3548497A4 (fr)
JP (3) JP7148533B2 (fr)
KR (3) KR102561697B1 (fr)
CN (2) CN116903624A (fr)
AU (3) AU2017366879C1 (fr)
BR (1) BR122021026889A8 (fr)
CA (1) CA3043502A1 (fr)
CO (1) CO2019006018A2 (fr)
IL (2) IL301470A (fr)
MA (1) MA46973A (fr)
MX (3) MX386520B (fr)
WO (1) WO2018102315A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130197000A1 (en) 2010-04-22 2013-08-01 Nihon University Drug and food/drink for preventing or improving cerebral dysfunction
US11072614B2 (en) * 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
EP3548487A4 (fr) 2016-11-29 2020-04-29 Censa Pharmaceuticals Inc. Forme polymorphe de sépiaptérine
CA3073957A1 (fr) 2017-09-01 2019-03-07 Censa Pharmaceuticals Inc. Composition pharmaceutique comprenant de la sepiapterine et ses utilisations
PT3801534T (pt) 2018-05-30 2026-04-28 Ptc Therapeutics Mp Inc Tratamento de fenilcetonúria com sepiapterina
WO2019232120A1 (fr) * 2018-05-30 2019-12-05 Censa Pharmaceuticals Inc. Sels pharmaceutiquement acceptables de sépiaptérine
MD3801536T2 (ro) 2018-05-30 2024-11-30 Ptc Therapeutics Mp Inc Administrarea sepiapterinei fără alimente pentru utilizare într-o metodă de creștere a expunerii plasmatice a sepiapterinei
IL290321B1 (en) 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment
IL291565B1 (en) * 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity
WO2021150983A1 (fr) 2020-01-24 2021-07-29 Ptc Therapeutics Mp, Inc. Méthodes de traitement de la maladie de parkinson avec de la sépiaptérine
WO2022173823A1 (fr) 2021-02-09 2022-08-18 Ptc Therapeutics Mp, Inc. Procédés de traitement de la covid-19 avec de la sépiaptérine
JP2024506336A (ja) 2021-02-09 2024-02-13 ピーティーシー セラピューティクス エムピー，インコーポレイテッド 膠芽腫の治療方法
KR20240064728A (ko) 2021-09-29 2024-05-13 피티씨 테라퓨틱스, 인크. 세피아프테린의 제약 조성물
WO2024249602A2 (fr) * 2023-05-30 2024-12-05 The Board Of Trustees Of The Leland Stanford Junior University Syndrome des jambes sans repos (rls) et mouvements périodiques des jambes pendant le sommeil (plms) : biomarqueur et cible médicamenteuse
CN117205164B (zh) * 2023-09-30 2024-07-26 山东新时代药业有限公司 一种盐酸沙丙蝶呤片剂及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) * 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
ATE218345T1 (de) 1994-08-05 2002-06-15 Suntory Ltd Arzneimittel gegen spinocerebellare degeneration
EP0854934A4 (fr) 1995-08-18 2000-09-06 Donald W Landry Detection de composes organiques par regulation de reactions catalysees par des anticorps
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
KR20060120147A (ko) 2003-10-31 2006-11-24 알타나 파마 아게 호흡 질환의 치료를 위한 ｂｈ4의 용도
KR20070005550A (ko) 2003-11-17 2007-01-10 바이오마린 파머수티컬 인크. 대사 장애 치료를 위한 조성물 및 방법
AU2004290692A1 (en) 2003-11-17 2005-06-02 Biomarin Pharmaceutical Inc. Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin
CN1894251B (zh) 2003-11-17 2011-06-29 默克和西伊公司 (6r)-l-赤型-四氢生物蝶呤二盐酸盐的晶型
BRPI0517088A (pt) * 2004-11-17 2008-09-30 Biomarin Pharm Inc formulação de comprimido estável
EP1819340A2 (fr) * 2004-12-08 2007-08-22 Biomarin Pharmaceutical Inc. Methodes et compositions de traitement de l'hypertension pulmonaire du nouveau-ne
DK1877370T3 (da) 2005-04-28 2009-05-11 Shiratori Pharm Fremgangsmåde til fremstilling af hydrazon-derivater
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
SI3461503T1 (sl) 2007-04-11 2022-04-29 Biomarin Pharmaceutical Inc. Postopki za dajanje tetrahidrobiopterina, povezani sestavki in postopki merjenja
AU2009224247B2 (en) * 2008-03-10 2013-12-12 Takeda Pharmaceutical Company Limited Crystal of benzimidazole compound
US20110144117A1 (en) 2008-08-12 2011-06-16 Orpha Swiss Gmbh Pharmaceutical Dosage Form Containing Tetrahydrobiopterin
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
MX2012002179A (es) * 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
US20130197000A1 (en) 2010-04-22 2013-08-01 Nihon University Drug and food/drink for preventing or improving cerebral dysfunction
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
KR20140021585A (ko) 2011-03-01 2014-02-20 루비콘 리서치 피브이티. 엘티디. 테트라하이드로바이옵테린의 안정한 조성물
US9216178B2 (en) * 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
ES2681345T3 (es) 2012-05-07 2018-09-12 Shiratori Pharmaceutical Co., Ltd. Método para producir sepiapterina y tetrahidrolactoilpterina
WO2017218421A1 (fr) 2016-06-13 2017-12-21 Meharry Medical College Modulation de la voie de l'oxyde nitrique synthase pour la santé buccale
US20190167598A1 (en) 2016-07-29 2019-06-06 Dipharma S.A. A novel treatment regimen involving sapropterin dihydrochloride
EP3548487A4 (fr) 2016-11-29 2020-04-29 Censa Pharmaceuticals Inc. Forme polymorphe de sépiaptérine
US11072614B2 (en) 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
TWI765936B (zh) 2016-11-29 2022-06-01 美商東京威力科創Ｆｓｉ股份有限公司 用以對處理腔室中之微電子基板進行處理的平移與旋轉夾頭
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CA3073957A1 (fr) 2017-09-01 2019-03-07 Censa Pharmaceuticals Inc. Composition pharmaceutique comprenant de la sepiapterine et ses utilisations
MD3801536T2 (ro) 2018-05-30 2024-11-30 Ptc Therapeutics Mp Inc Administrarea sepiapterinei fără alimente pentru utilizare într-o metodă de creștere a expunerii plasmatice a sepiapterinei
WO2019232120A1 (fr) 2018-05-30 2019-12-05 Censa Pharmaceuticals Inc. Sels pharmaceutiquement acceptables de sépiaptérine
PT3801534T (pt) 2018-05-30 2026-04-28 Ptc Therapeutics Mp Inc Tratamento de fenilcetonúria com sepiapterina
IL290321B1 (en) 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment
IL291565B1 (en) 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity

Also Published As

Publication number Publication date
BR122021026889A8 (pt) 2022-11-22
AU2022203481B2 (en) 2023-10-19
KR102789662B1 (ko) 2025-04-03
AU2017366879B2 (en) 2022-02-24
IL301470A (en) 2023-05-01
US20250230164A1 (en) 2025-07-17
CN110248948B (zh) 2023-07-28
AU2024200344A1 (en) 2024-02-08
EP3548497A4 (fr) 2020-09-02
CN110248948A (zh) 2019-09-17
BR112019010222A8 (pt) 2022-11-22
MX386520B (es) 2025-03-19
US12269829B2 (en) 2025-04-08
EP3548497A1 (fr) 2019-10-09
CA3043502A1 (fr) 2018-06-07
JP2019535836A (ja) 2019-12-12
KR20230117467A (ko) 2023-08-08
NZ753504A (en) 2025-10-31
KR20190086686A (ko) 2019-07-23
US11072614B2 (en) 2021-07-27
KR20250051124A (ko) 2025-04-16
KR102561697B1 (ko) 2023-07-28
US20210300930A1 (en) 2021-09-30
MX2019006206A (es) 2019-08-14
US20190308975A1 (en) 2019-10-10
WO2018102315A1 (fr) 2018-06-07
JP2024123011A (ja) 2024-09-10
US11773097B2 (en) 2023-10-03
AU2022203481A1 (en) 2022-06-16
AU2017366879C1 (en) 2022-08-11
BR112019010222A2 (pt) 2019-08-27
AU2017366879A1 (en) 2019-05-30
CN116903624A (zh) 2023-10-20
IL266955A (en) 2019-07-31
AU2024200344B2 (en) 2025-11-06
IL266955B1 (en) 2023-05-01
US20240043426A1 (en) 2024-02-08
JP7148533B2 (ja) 2022-10-05
MX2021011676A (es) 2021-10-22
JP2023002532A (ja) 2023-01-10
WO2018102315A8 (fr) 2018-09-07
MX2021011683A (es) 2021-10-22
IL266955B2 (en) 2023-09-01
CO2019006018A2 (es) 2019-06-19
BR122021026889A2 (fr) 2019-08-27

Similar Documents

Publication Publication Date Title
IL284874A (en) Valbenazine salts and polymorphs thereof
IL265166B (en) Anti-influenza virus pyrimidine derivatives
IL266955A (en) Polymorphs of spiafatrin and its salts
IL267530A (en) Polymorphs
EP3383883A4 (fr) Sels de conjugués en cancéro-thérapie
LT3457851T (lt) Sobetiromo dariniai
LT3402792T (lt) Chinolin-2-ono dariniai
DK3558961T3 (da) Polymorfer
EP3564216A4 (fr) Dérivé pyrimidine
DK3286260T3 (da) Polyolefinrør
EP3426159A4 (fr) Identification de structures anatomiques
PT3247711T (pt) Novos sais e polimorfos de scy-078
DK3372589T3 (da) Pyrimidinderivat
DE102016006280A8 (de) Flächengebilde
DK3380465T3 (da) Diaminopyridinderivativer
DK3411561T3 (da) Borehulskompletteringssystem
EP3546539A4 (fr) Corps sous forme de rouleau
EP3470085A4 (fr) Dialysat péritonéal biocompatible
IL265161A (en) A lintel
MA50669A (fr) Nouveaux sels
EP3368527A4 (fr) Sels de palbociclib
FIC20170055I1 (fi) Nusinerseeni tai sen suolat
DE112017003625A5 (de) Difluorstilben-Derivate
FR3050606B1 (fr) Sillonneuse droite triangulaire isocele
ITUA20162617A1 (it) Avvolgibile